Simultaneous binding of covalent immunochemotherapeutic combinations like gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu] at two different over-expressed trophic receptor types on the exterior surface membrane of a single cancer cell population in-vivo offers the potential to attain a third plane of additive and synergistic anti-neoplastic cytotoxicity from innate immune response mechanisms. The gene discussed is EGFR; the disease is cancer.